英批準首款抗新冠口服藥

The first pill designed to treat symptomatic Covid-19 has been approved by the UK medicines regulator.

英國藥品監(jiān)管機構(gòu)批準了首款用于治療癥狀性新冠肺炎的藥物。

The tablet - molnupiravir - will be given twice a day to vulnerable patients recently diagnosed with the disease.

近期確診新冠肺炎的虛弱患者將每天服用兩次莫那比拉韋。

In clinical trials, the pill, originally developed to treat flu, cut the risk of hospitalization or death by about half.

在臨床試驗中，該藥物將因感染新冠病毒住院或死亡的風險降低了一半左右。該藥物原本用于治療流感。

Health Secretary Sajid Javid said the treatment was a "gamechanger" for the most frail and immuno-suppressed.

英國衛(wèi)生大臣賽義德•賈維德稱，這種藥物對身體虛弱和免疫功能不全的人來說意義重大。

Molnupiravir, developed by the US drug companies Merck, Sharp and Dohme (MSD) and Ridgeback Biotherapeutics, is the first antiviral medication for Covid-19, which can be taken as a pill rather than injected or given intravenously.

莫那比拉韋由美國制藥公司默克和Ridgeback生物治療公司研發(fā)，是第一款抗新冠口服藥，而非靜脈注射類藥物。

The UK has agreed to purchase 480,000 courses, with the first deliveries expected in November.

英國政府已批準訂購48萬個療程，首批藥物預計于11月交付。

The drug needs to be given within five days of symptoms developing to be most effective.

該藥物需在出現(xiàn)癥狀五天內(nèi)服用才能發(fā)揮最大療效。